Treatment of Persons Who Inject Drugs (PWID): Treatment as Prevention
AASLD LiverLearning®. Grebely J. Nov 14, 2016; 154726
Topic: Diagnosis and Natural History
Label: HCV Symposium: Challenges in the DAA Era
Disclosure(s): ABBVIE, BMS, GILEAD, MERCK
Dr. Jason Grebely
Dr. Jason Grebely

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting. A LiverLearning® Subscription ($150.00 US) grants access to LiverLearning® Premium content for one year after date of purchase. Click here to purchase your Premium Access Subscription now.


Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions